View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 1, 2018

AstraZeneca faces US DOJ probe for alleged funding of Iraqi terrorists

The US Department of Justice (DOJ) has reportedly launched an investigation into a lawsuit that alleges AstraZeneca bribed terrorists in order to win contracts with the Iraqi Ministry of Health.

The US Department of Justice (DOJ) has reportedly launched an investigation into a lawsuit that alleges AstraZeneca bribed terrorists in order to win contracts with the Iraqi Ministry of Health.

The DOJ probe is set to assess the claims made in a litigation filed in October last year against companies AstraZeneca, Pfizer, Roche, Johnson & Johnson and General Electric.

The complaint was lodged in the District of Columbia federal court by US nationals who were wounded or the kin of those killed in Iraq between 2005 and 2009.

In its SEC filing last month, AstraZeneca confirmed that it will cooperate with the anti-corruption DOJ probe.

A statement of the company read: “AstraZeneca has received an inquiry from the US Department of Justice in connection with an anti-corruption investigation relating to activities in Iraq, including interactions with the Iraqi government and certain of the same matters alleged in the lawsuit.”

An AstraZeneca spokesperson told Fierce Pharma that the company has a ‘robust and dynamic compliance programme, and we refuse to tolerate bribery or any other form of corruption’.

“AstraZeneca has received an inquiry from the US Department of Justice in connection with an anti-corruption investigation relating to activities in Iraq.”

The lawsuit claims that terrorists controlled the Iraqi Ministry of Health and pharmaceutical companies successfully gained contracts from the ministry by bribing these terrorists.

This financing is said to have directly supported an Iran-backed, Hezbollah-trained militia responsible for killing or wounding numerous US citizens.

The contracts and associated transactions date back to Saddam Hussein’s regime (1979-2003).

According to media sources, the accused companies said that the then US Government encouraged business with the Iraq.

The defendants stated: “The US expressly encouraged companies to sell and to donate to the ministry millions of dollars’ worth of medicines and medical supplies.”

Meanwhile, the lawsuit seeks compensatory and punitive damages from the companies under the federal Anti-Terrorism Act.

Related Companies

Topics in this article: , , ,
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU